Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 50 of 50 matching drugs for EPHB2 — including drugs targeting any of its 14 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
vandetanib EPHB2 Direct yes 0
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSK SSL via CSK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CSK SSL via CSK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
nintedanib LCK SSL via LCK 2
nintedanib, pembrolizumab LCK SSL via LCK 2
afatinib, dasatinib, palbociclib, everolimus, olaparib CSK SSL via CSK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
bevacizumab, dasatinib, placebo CSK SSL via CSK 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CSK SSL via CSK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CSK SSL via CSK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, laboratory biomarker analysis, physiologic testing CSK SSL via CSK 1
dasatinib, laboratory biomarker analysis, physiologic testing LCK SSL via LCK 1
dasatinib, mfolfox6 CSK SSL via CSK 1
dasatinib, mfolfox6 LCK SSL via LCK 1
dasatinib, pharmacological study CSK SSL via CSK 1
dasatinib, pharmacological study LCK SSL via LCK 1
dasatinib, temozolomide, placebo, radiation therapy CSK SSL via CSK 1
dasatinib, temozolomide, placebo, radiation therapy LCK SSL via LCK 1
mitapivat, mitapivat-matching placebo, mitapivat-matching placebo PKLR SSL via PKLR 1
ponatinib LCK SSL via LCK 1
afatinib dimaleate EGFR SSL via EGFR yes 0
cetuximab EGFR SSL via EGFR yes 0
dasatinib LCK SSL via LCK yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
midostaurin PRKCZ SSL via PRKCZ yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
panitumumab EGFR SSL via EGFR yes 0
pazopanib LCK SSL via LCK yes 0
pazopanib hydrochloride LCK SSL via LCK yes 0
regorafenib EGFR SSL via EGFR yes 0
vandetanib EGFR SSL via EGFR yes 0
vandetanib LCK SSL via LCK yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.